<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>molecular targeted therapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/molecular-targeted-therapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Oct 2026 04:03:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>molecular targeted therapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Glioblastoma Pipeline Shifts to Biomarker-Guided Combination Therapies</title>
		<link>https://bioengineer.org/glioblastoma-pipeline-shifts-to-biomarker-guided-combination-therapies/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 18 Oct 2026 04:03:27 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Blood-brain barrier]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[combination therapy]]></category>
		<category><![CDATA[dendritic cell vaccines]]></category>
		<category><![CDATA[Gene Therapy]]></category>
		<category><![CDATA[Glioblastoma]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[molecular targeted therapy]]></category>
		<category><![CDATA[oncolytic virus]]></category>
		<category><![CDATA[tumor metabolism]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=433663</guid>

					<description><![CDATA[A new Oncoscience perspective maps the 2025–2026 glioblastoma clinical trial pipeline across four mechanistic domains, showing how biomarker-guided selection and rational combination strategies are reshaping treatment development.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">433663</post-id>	</item>
	</channel>
</rss>
